Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Announces Opening of its GMP Bioproduction Facility in France

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
Enables accelerated process development and production of proteins/monoclonal antibodies.

Merck Millipore has announced the opening of its advanced GMP bioproduction facility in Martillac, France, offering a full, single-use process train to speed a molecule's journey to the clinic.

The site will serve users of Merck Millipore's Provantage™ Biodevelopment and Clinical Supply Solutions, an innovative, "open source" manufacturing option that incorporates the latest technologies for upstream and downstream processes.

The open source approach provides customers with greater control over production.

With a traditional outsourcing model, the customer's process must fit the facility and the contract manufacturer controls the process.

With ProVantage™ Solutions, Merck Millipore develops the process for further use by the customer.

At the new facility, Merck Millipore provides access to proven technologies, process development expertise and validation services, offering a robust template that makes it possible to go from clone selection to GMP product in only 12 months.

The facility offers GMP production of mammalian proteins for pre-clinical to phase II production at the 50 L to 1,250 L scale.

For phase III and commercial production, customers can transfer manufacturing to any location, at any scale.

This freedom brings enhanced flexibility to the molecule development and the manufacturing process.

"Merck Millipore leverages more than 25 years of biomanufacturing experience with 150 molecules in our new facility in France," said Christophe Couturier, Vice President of Services and Solutions, Merck Millipore.

Couturier continued, "As the basis for Provantage™ Solutions, our experts complement customers' internal capabilities in a way that combines the best of in-house production and conventional outsourcing. The end result is increased productivity and an accelerated time to market."

For more information on the new facility and Provantage™ Solutions, please visit

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Announces Exclusive Agreement with Julphar Diabetes
Collaboration to offer non-animal origin, recombinant human insulin as cell culture media supplement.
Wednesday, August 08, 2012
Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
Bulpin appointed as head of the company's process solutions business unit.
Wednesday, May 02, 2012
Merck Millipore and CCRM Collaborate to Optimize Conditions for Large-scale Stem Cell Cultivation
Collaboration to deliver optimized methodologies for cultivation of stem cells on microcarriers in Mobius® CellReady bioreactor systems.
Tuesday, March 13, 2012
Scientific News
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos